long intergenic non-protein coding RNA 1016Genealiases: []
Q-omics provides the consensus-scored LINC01016 profile across patient tissues and cancer cell-line models. LINC01016 expression is associated with patient survival in 21 of 34 cancer types, with the highest sampling consensus in KIRP. Among the 18 cancer types available for tumor–normal comparison, LINC01016 is differentially expressed in 10, with the highest sampling consensus in COAD. Additionally, LINC01016 RNA expression shows 10,491 significant gene co-expression associations, with the highest sampling consensus in SARC. Together, these results highlight KIRP, COAD, and SARC as cancer lineages where LINC01016 shows reproducible signals across survival, tumor–normal expression, and patient cross-omics analyses.
Every result is evaluated using two consensus scores. Sampling consensus measures how consistently a finding is reproduced within a cancer lineage across different conditions. Lineage consensus measures how broadly the result is shared across cancer types, distinguishing pan-cancer signals from lineage-specific patterns.
Premium analyses for LINC01016 — synthetic lethality, tumor antigen, and pembrolizumab response.
This table summarizes LINC01016 survival associations across molecular data types. LINC01016 RNA expression shows survival associations in the most cancer types (21). The rightmost column indicates the cancer type with the highest sampling consensus for each molecular layer.
This table ranks reproducible LINC01016 RNA expression–survival associations across cancer types. High LINC01016 expression shows unfavorable associations in KIRP and KIRC, but favorable associations in BRCA, MESO, ESCA and READ. The KIRP Kaplan–Meier curve shows clear separation, with the high-expression group declining faster, consistent with the unfavorable association (log-rank p < 0.001). Together, the overview and detailed table identify KIRP as the clearest survival context for LINC01016 RNA expression.
This table summarizes LINC01016 tumor–normal expression differences by data type. RNA shows broader differences across cancer types, with a lineage consensus of 10. The strongest signals are observed in LUAD for RNA.
This table ranks reproducible tumor–normal expression differences for LINC01016. A negative fold-change indicates higher expression in normal tissue than in tumor tissue. LINC01016 shows lower tumor expression in COAD, LUAD, UCEC, KICH, LUSC and READ. The COAD box plot shows higher LINC01016 RNA expression in normal versus tumor tissue (log2 FC = −0.288, t-test p < 0.001).
This table shows molecular features associated with LINC01016 in patient tissues and cancer cell lines. In patient samples, LINC01016 shows the broadest associations at the RNA and protein expression levels, with SARC recurring as the lineage with the largest associated feature set.
